A Neuroradiologist’s Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults

Benjamin M. Ellingson, Francesco Sanvito, Timothy F. Cloughesy, Raymond Y. Huang, Javier E. Villanueva-Meyer, Whitney B. Pope, Daniel P. Barboriak, Lalitha K. Shankar, Marion Smits, Timothy J. Kaufmann, Jerrold L. Boxerman, Michael Weller, Evanthia Galanis, John de Groot, Mark R. Gilbert, Andrew B. Lassman, Mark S. Shiroishi, Ali Nabavizadeh, Minesh Mehta, Roger Stupp, Wolfgang Wick, David A. Reardon, Michael A. Vogelbaum, Martin van den Bent, Susan M. Chang and Patrick Y. Wen

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

SUMMARY: Radiographic assessment plays a crucial role in the management of patients with central nervous system (CNS) tumors, aiding in treatment planning and evaluation of therapeutic efficacy by quantifying response. Recently, an updated version of the Response Assessment in Neuro-Oncology (RANO) criteria (RANO 2.0) was developed to improve upon prior criteria and provide an updated, standardized framework for assessing treatment response in clinical trials for gliomas in adults. This article provides an overview of significant updates to the criteria including (1) the use of a unified set of criteria for high and low grade gliomas in adults; (2) the use of the post-radiotherapy MRI scan as the baseline for evaluation in newly diagnosed high-grade gliomas; (3) the option for the trial to mandate a confirmation scan to more reliably distinguish pseudoprogression from tumor progression; (4) the option of using volumetric tumor measurements; and (5) the removal of subjective non-enhancing tumor evaluations in predominantly enhancing gliomas (except for specific therapeutic modalities). Step-by-step pragmatic guidance is hereby provided for the neuroradiologist and imaging core lab involved in operationalization and technical execution of RANO 2.0 in clinical trials, including the display of representative cases and in-depth discussion of challenging scenarios.

ABBREVIATIONS:

BTIP
Brain Tumor Imaging Protocol
CE
Contrast-Enhancing
CNS
Central Nervous System
CR
Complete Response
ECOG
Eastern Cooperative Oncology Group
HGG
High-Grade Glioma
IDH
Isocitrate Dehydrogenase
IRF
Independent Radiologic Facility
KPS
Karnofsky Performance Status
LGG
Low-Grade Glioma
MR
Minor Response
mRANO
Modified RANO
NANO
Neurological Assessment in Neuro-Oncology
ORR
Objective Response Rate
OS
Overall Survival
PD
Progressive Disease
PFS
Progression-Free Survival
PR
Partial Response
PsP
Pseudoprogression
RANO
Response Assessment in Neuro-Oncology
RECIST
Response Evaluation Criteria In Solid Tumors
RT
Radiation Therapy
SD
Stable Disease
Tx
Treatment
View Full Text

Log in through your institution

Advertisement